ArticleLeukemia2022

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Anne Sophie Kubasch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.